Earnings Preview: Halozyme Therapeutics
Portfolio Pulse from Benzinga Insights
Halozyme Therapeutics (NASDAQ:HALO) is scheduled to release its quarterly earnings report on February 20, 2024, with an expected EPS of $0.83. The company's past earnings performance shows a mix of beats and misses, with the stock price reacting accordingly. Shares are currently trading at $35.91, down 27.31% over the last 52 weeks. Investors are looking for positive guidance for the next quarter.
February 19, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Halozyme Therapeutics is expected to report an EPS of $0.83 for the upcoming quarter. Historical performance shows significant stock price movements post-earnings. Currently, shares are down 27.31% over the last year.
Given HALO's history of stock price movements post-earnings, the upcoming report could lead to positive momentum if the company beats estimates and provides strong guidance. However, the stock's recent downtrend indicates investor caution.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100